Corporate Presentation September 2022 NASDAQ: OTLK outlooktherapeutics.com | --- | --- | --- | |---------------|---------------------------------------------------------------------------------------|-------| | | | | | | Enhancing the standard of care for retinal disorders by working to achieve the first | | | ophthalmology | FDA approval for bevacizumab in | 2 | Disclaimer This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ("Outlook Therapeutics" or the "Company") based ...